PCM
PCRX icon

Piermont Capital Management’s Pacira BioSciences PCRX Stock Holding History

Piermont Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,500
Closed -$297K – 253
2017
Q4 		$297K Sell
6,500
-360
-5% -$14.3K 0.1% 216
2017
Q3 		$258K Sell
6,860
-7,020
-51% -$282K 0.09% 228
2017
Q2 		$662K Buy
+13,880
New +$644K 0.19% 204

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Piermont Capital Management's PCRX Position: Q1 2018 in Review

Piermont Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 6,500 shares — an estimated $297K sold.

Piermont Capital Management first reported a position in PCRX in Q2 2017 and held it in 3 quarters. The position peaked at $662K in Q2 2017. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

  • Piermont Capital Management reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
  • Piermont Capital Management sold 6,500 Pacira BioSciences shares in Q1 2018, an estimated $297K.
  • Piermont Capital Management first reported a position in Pacira BioSciences in Q2 2017 and held it in 3 quarters.
  • Piermont Capital Management's Pacira BioSciences position peaked at $662K in Q2 2017.
  • 168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on Piermont Capital Management's 13F filing for Q1 2018, filed 9 May 2018.